

Bone Metastasis Treatments, Major Therapeutic Frontiers

Da-Yong Lu* and Bin Xu*School of Life Sciences, Shanghai University, Shanghai, China****Corresponding Author:** Da-Yong Lu, School of Life Sciences, Shanghai University, Shanghai, China.**Received:** April 26, 2021**Published:** June 01, 2021© All rights are reserved by **Da-Yong Lu and Bin Xu****Introduction**

Cancer is the secondary leading disease-induced human mortality worldwide. 60 - 90% cancer mortality is caused by neoplasm metastasis [1-4]. Currently, anticancer drugs are the foremost therapeutic selection because a lot of diversity of tumor origins and drug responses. Several pathways can improve these therapeutic responses and benefiting for bone metastasis treatment;

Future Direction

Finding key genetic or molecular factors that is involving bone metastasis [5].

Development of high-active anticancer or antimetastatic drugs [6-9].

Drug mechanisms and targeting study [10,11].

Herbal medicine may promote human physiological conditions and integrity [12-14].

Personalized medicine is a growing drug selection paradigm that may optimize drug treatment against cancer growth and metastasis [15-25].

Drug combination is an important pathway to promote clinical outcomes yet much efforts should be made to streamline clinical practice [26,27].

Mathematics and computational aids [28-31].

Bibliography

1. Lambert AW, *et al.* "Emerging biological principles of metastasis". *Cell* 168 (2017): 670-691.
2. Ahmad AS, *et al.* "Trends in the lifetime risk of developing cancer in Great Britain; Comparison of risk for those born from 1930-1960". *British Journal of Cancer* 112 (2015): 943-947.
3. Mehlen P and Puisieux A. "Metastasis; a question of life or death". *Nature Reviews Cancer* 6 (2006): 449-458.
4. Weidenfeld K and Barkan D. "EMT and stemness in tumor dormancy and outgrowth: Are they intertwined processes?" *Frontiers in Oncology* 8 (2018): 381.
5. Pantano F, *et al.* "Integrin alpha 5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions". *Oncogene* 40 (2021): 1284-1299.
6. Lu DY and Che JY. "Bone disease treatments, importance of technical supports". *Acta Scientific Orthopaedics* 4.4 (2021): 55-57.
7. Lu DY, *et al.* "Cancer Metastasis treatments". *Current Drug Therapy* 8.1 (2013): 24-29.
8. Lu DY, *et al.* "Anti-metastatic drug development, work out towards new direction". *Medicinal Chemistry* 8.7 (2018): 192-196.
9. Lu DY and Lu TR. "Antimetastatic activities and mechanisms of bisdioxopiperazine compounds". *Anti-Cancer Agent Medicinal Chemistry* 10.7 (2010): 564-570.

10. Zhu H., *et al.* "DJ-1 mediates the resistance of cancer cells to dihydroartemisinin through cancer cells through reactive oxygen species removal". *Free Radical Biology and Medicine* 71 (2014): 121-132.
11. Lu DY., *et al.* "Development of antimetastatic drugs by targeting tumor sialic acids". *Scientia Pharmaceutica* 80.3 (2012): 497-508.
12. Agarwal N., *et al.* "Natural herbs as anticancer drugs". *International Journal of PharmTech Research* 4.3 (2012): 1142-1153.
13. Lu DY., *et al.* "Natural drug cancer treatment strategies from herbal medicine to chemical or biological drug". *Studies in Natural Products Chemistry* 66 (2020): 91-115.
14. Lu DY and Lu TR. "Herbal medicine in new era". *Hospice Palliative Medicine International Journal* 3.4 (2019): 125-130.
15. Lu DY., *et al.* "Individualized cancer chemotherapy integrating drug sensitivity tests, pathological profile analysis and computational coordination-an effective strategy to improve clinical treatment". *Medical Hypotheses* 66.1 (2006): 45-51.
16. Lu DY. "Personalized cancer chemotherapy, an effective way for enhancing outcomes in clinics". Woodhead Publishing, Elsevier, UK (2014).
17. Volm M and Efferth T. "Prediction of cancer drug resistance and implications for personalized medicine". *Frontiers in Oncology* (2015): 282.
18. Lu DY., *et al.* "Anticancer drug sensitivity testing, a historical review and future perspectives". *Current Drug Therapy* 10.1 (2015): 44-55.
19. Lu DY and Lu TR. "Drug sensitivity testing, a unique drug selection strategy". *Advances in Biomarker Sciences and Technology* 2 (2020): 59-66.
20. Lu DY., *et al.* "Cancer bioinformatics for update anticancer drug developments and personalized therapeutics". *Reviews on Recent Clinical Trials* 12.2 (2017): 101-110.
21. Lu DY., *et al.* "Pharmacogenetics of cancer therapy: breakthroughs from beyond?" *Future Science OA* 1.4 (2015): 80.
22. Montero J., *et al.* "Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy". *Cell* 160 (2015): 977-989.
23. Popova AA and Levkin PA. "Precision medicine in oncology: In vitro drug sensitivity and resistance test (DSRT) for selection of personalized anticancer therapy". *Advanced Therapeutics* (2020): 1900100.
24. Hyman DH., *et al.* "Implementing genome-driven oncology". *Cell* 168 (2017): 584-599.
25. Lu DY., *et al.* "Individualized cancer therapy, future approaches". *Current Pharmacogenomics and Personalized Medicine* 16.2 (2018): 156-163.
26. Lu DY., *et al.* "Anticancer drug combination, how far we can go through?" *Anti-Cancer Agents in Medicinal Chemistry* 17.1 (2017): 21-28.
27. Lu DY., *et al.* "Drug combination in clinical cancer treatment". *Reviews on Recent Clinical Trials* 12.3 (2017): 202-211.
28. Franssen L., *et al.* "A mathematical framework for modeling the metastatic spread of cancer". *Bulletin of Mathematical Biology* 81 (2019): 1965-2010.
29. Gerlee P and Johanson M. "Inferring rates of metastatic dissemination using stochastic network models". *PLOS Computational Biology* 15.4 (2019): e1006868.
30. Freedman DH. "Hunting for new drugs with AI". *Nature* 576 (2019): s49-s53.
31. Lu DY., *et al.* "Anatomic approaches for cancer metastatic study". *EC Clinical and Experimental Anatomy* 3.9 (2020): 32-34.

Volume 4 Issue 7 July 2021

© All rights are reserved by Da-Yong Lu and Bin Xu.